Genencor Launches Industry Transforming Technology for Ethanol Production
New enzyme technology removes the need for energy-intensive, costly cook step
Advertisement
Genencor International, Inc. announced the availability of novel enzyme technology for the ethanol industry that could lead to improved energy balance and reduced production costs while obtaining higher output. The first product from its line of STARGEN(TM) granular starch hydrolyzing enzymes has the potential to pave the way for the emergence of biorefineries.
Until recently, ethanol plants have cooked grains and other feedstocks with thermostable enzymes to begin the process of converting starch to fermentable sugars and ultimately to ethanol. Genencor's STARGEN(TM) enzymes include blends of an alpha amylase and a glucoamylase that convert granular or uncooked starch to fermentable sugars on a continuous basis through a simultaneous saccharification and fermentation process. Some of the potential advantages of this new technology include improved productivity, reduced energy consumption, higher ethanol yields and savings on capital expenses by reducing overall unit operations.
"This new, low energy technology offers the ethanol industry significant added value with fewer processing steps requiring less energy, materials and capital. It should be equally useful to producers to accelerate the development of biobased manufacturing processes and products that require low-cost carbon," said Thomas J. Pekich, president of Genencor International. "Together, technology advances like STARGEN(TM) enzymes will lead to a more sustainable environment and lessen dependence on foreign oil."
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
DeCODE Discovery Sheds Light on Risk of the Most Common Form of Skin Cancer - Latest discoveries add to understanding of individual risk of basal cell carcinoma, and are integrated into the deCODEme™ personal genome analysis scan
Biovitrum has Successfully Completed the First Phase I Trial of its 5-HT6 Receptor Antagonist (BVT.74316)
